<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04029337</url>
  </required_header>
  <id_info>
    <org_study_id>HL-2019-01</org_study_id>
    <nct_id>NCT04029337</nct_id>
  </id_info>
  <brief_title>An Early Feasibility Study of the HighLife 28mm Trans-Septal Transcatheter Mitral Valve Replacement System</brief_title>
  <official_title>An Early Feasibility Study of the HighLife 28mm Trans-Septal Transcatheter Mitral Valve Replacement System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HighLife SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HighLife SAS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to evaluate the feasibility, safety and performance of the HighLife trans-septal&#xD;
      Transcatheter Mitral Valve in patients with moderate-severe and severe mitral regurgitation&#xD;
      who are at high risk for surgical treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">April 2026</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device Safety</measure>
    <time_frame>30 days</time_frame>
    <description>Freedom from major adverse events</description>
  </primary_outcome>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Mitral Regurgitation</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HighLife Transcatheter Mitral Valve Replacment</intervention_name>
    <description>Transcatheter mitral valve replacement</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Age ≥ 18 years 2. Moderate-severe or severe mitral regurgitation (&gt; 3+)&#xD;
&#xD;
               -  For Degenerative MR: EROA ≥ 40 mm2 or regurgitant volume ≥ 60ml&#xD;
&#xD;
               -  For Secondary MR: EROA &gt; 30 mm2 or regurgitant volume &gt; 45ml (i.e., MR ≥&#xD;
                  moderate-severe or severe by ASE criteria) 3. Patient has New York Heart&#xD;
                  Association (NYHA) Functional Class II, III or ambulatory IV 4. Patient is under&#xD;
                  guideline directed medical therapy, as reviewed and confirmed by the local&#xD;
                  multidisciplinary Heart Team, for at least one month 5. Patient is high-risk for&#xD;
                  open-heart surgery based on the assessment of the multidisciplinary Heart Team&#xD;
                  using standard scoring systems and consideration of co-morbidities, frailty, and&#xD;
                  disability 6. Patient meets the anatomical criteria for HighLife valve 7. Patient&#xD;
                  is willing to participate in the study and provides signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any stroke/TIA within 30 days&#xD;
&#xD;
          2. Severe symptomatic carotid stenosis (&gt; 70% by non-invasive imaging)&#xD;
&#xD;
          3. Active infections requiring antibiotic therapy&#xD;
&#xD;
          4. Active ulcer or gastro-intestinal bleeding in the past 3 months&#xD;
&#xD;
          5. History of bleeding diathesis, coagulopathy or refusal of future blood transfusion&#xD;
&#xD;
          6. Patients in whom TEE is not feasible&#xD;
&#xD;
          7. Patients who are pregnant or lactating, or plan to get pregnant in the next 12 months.&#xD;
&#xD;
          8. Patient is unable to comply with the follow-up schedule and assessments&#xD;
&#xD;
          9. Participation in another clinical investigation at the time of inclusion&#xD;
&#xD;
         10. Patient has known allergies to the device components or contrast medium&#xD;
&#xD;
         11. Patient cannot tolerate anticoagulation or antiplatelet therapy&#xD;
&#xD;
         12. Patients with a life expectancy of less than 12 months due to non-cardiac conditions&#xD;
&#xD;
         13. Patient had permanent pacemaker, or similar device with implantable cardiac leads&#xD;
             (i.e. resynchronization therapy) within the last 3 months&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 20, 2019</study_first_submitted>
  <study_first_submitted_qc>July 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2019</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

